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Abstract. Cell lines established from the TH-MYCN transgenic 
murine model of neuroblastoma are a valuable preclinical, 
immunocompetent, syngeneic model of neuroblastoma, for 
which knowledge of their p53 pathway status is important. In 
this study, the Trp53 status and functional response to Nutlin-3 
and ionising radiation (IR) were determined in 6 adherent 
TH-MYCN transgenic cell lines using Sanger sequencing, 
western blot analysis and flow cytometry. Sensitivity to struc-
turally diverse MDM2 inhibitors (Nutlin-3, MI-63, RG7388 
and NDD0005) was determined using XTT proliferation 
assays. In total, 2/6 cell lines were Trp53 homozygous mutant 
(NHO2A and 844MYCN+/+) and 1/6 (282MYCN+/-) was Trp53 
heterozygous mutant. For 1/6 cell lines (NHO2A), DNA from 
the corresponding primary tumour was found to be Trp53 wt. 
In all cases, the presence of a mutation was consistent with 
aberrant p53 signalling in response to Nutlin-3 and IR. In 
comparison to TP53 wt human neuroblastoma cells, Trp53 wt 
murine control and TH-MYCN cell lines were significantly less 
sensitive to growth inhibition mediated by MI-63 and RG7388. 
These murine Trp53 wt and mutant TH-MYCN cell lines are 
useful syngeneic, immunocompetent neuroblastoma models, 
the former to test p53-dependent therapies in combination with 
immunotherapies, such as anti-GD2, and the latter as models 
of chemoresistant relapsed neuroblastoma when aberrations in 
the p53 pathway are more common. The spontaneous devel-
opment of Trp53 mutations in 3 cell lines from TH-MYCN 
mice may have arisen from MYCN oncogenic driven and/or 
ex vivo selection. The identified species-dependent selectivity 
of MI-63 and RG7388 should be considered when interpreting 
in vivo toxicity studies of MDM2 inhibitors.
Introduction
Neuroblastoma, an embryonal malignancy of the developing 
sympathetic nervous system, remains one of the most difficult 
paediatric cancers to cure with <50% of high-risk patients being 
long-term survivors despite intensive multi-modal therapy. 
MYCN amplification occurs in ~50% of high-risk cases, asso-
ciated with rapid tumour progression and a poor prognosis (1). 
The role of MYCN in neuroblastoma tumourigenesis has been 
demonstrated by the generation of TH-MYCN transgenic mice 
in 1997 through the transfer of a construct incorporating human 
MYCN cDNA under the control of the rat tyrosine hydroxylase 
promoter into the nucleus of fertilised murine oocytes and 
subsequent integration into genomic DNA (2,3). The tyrosine 
hydroxylase promoter leads to tissue-targeted overexpression 
of human MYCN in neural crest cells, and mice develop spon-
taneous highly penetrant abdominal and para-spinal thoracic 
tumours consistent with sites of human neuroblastoma (2). 
Tumour penetrance and growth have been shown to be related 
to MYCN gene dosage where homozygotes develop tumours 
with increased incidence and decreased latency (2,4). Analysis 
of TH-MYCN tumours has shown that they recapitulate many 
histological features of human neuroblastoma with varying 
degrees of neuronal differentiation and express synaptophysin 
and neuron-specific enolase (2). Moreover, tumours also 
exhibit chromosomal changes syntenic with those observed 
in human neuroblastoma tumours, such as gain of chromo-
some 17 (2,4). The TH-MYCN transgenic mouse is now a 
well-established model of neuroblastoma, and a panel of 
homozygous and hemizygous TH-MYCN cell lines have been 
derived from tumour resections from these mice, similarly 
reflecting both the genetic and biological features of human 
neuroblastoma (5). Although micrometastases can occur, 
one major limitation of the TH-MYCN transgenic model in 
preclinical drug development studies is the very low incidence 
of clinically relevant metastases to sites such as bone marrow, 
thus limiting its usefulness as a model for high-risk metastatic 
neuroblastoma (6). To overcome this, TH-MYCN cell lines 
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have been used to generate highly valuable orthotopic and 
pseudometastatic syngeneic models of neuroblastoma in an 
immunocompetent background (7,8). This is of particular 
importance as immunotherapies, such as anti-GD2 antibody 
are currently standard of care for the treatment of children 
with high-risk neuroblastoma.
The tumour suppressor gene, TP53, is critical in main-
taining genomic stability and is mutationally inactivated 
in >50% of all human malignancies (9). Abnormalities in 
the p53 pathway can contribute to tumour resistance against 
ionising radiation (IR) and cytotoxic chemotherapies (10-13). 
In neuroblastoma tumours and cell lines established at 
diagnosis, TP53 mutations are rare; however an increased 
frequency of mutations has been reported at relapse/post-
chemotherapy (14-16). Knowledge of Trp53 genetic and 
functional status in TH-MYCN cell lines is important if 
they are to be used in preclinical syngeneic neuroblastoma 
models.
In this study, we characterised the genetic and functional 
status of p53 in 6 adherent TH-MYCN transgenic murine cell 
lines, and demonstrate that 3/6 cell lines have Trp53 mutations 
and could be used to generate valuable syngeneic models of p53 
non-functional relapsed neuroblastoma. Moreover, we provide 
evidence of the species-dependent selectivity of some MDM2 
inhibitors, which should be considered when selecting murine 
models for preclinical toxicity testing of MDM2 inhibitors.
Materials and methods
Cell lines. The TH-MYCN transgenic murine cell lines used 
were MYCN homozygous NHO2A, 844MYCN+/+, 3261MYCN+/+, 
3394MYCN+/+, 3399MYCN+/+ and hemizygous 282MYCN+/-. The 
NHO2A cell line has been previously described (5) and 
together with NHO2A mouse tumour DNA, was obtained 
from Professor Michelle Haber (Children's Cancer Institute, 
Sydney, NSW, Australia). All other previously unre-
ported TH-MYCN cell lines were established from the 
TH-MYCN colony at the Children's Hospital of Philadelphia 
(Philadelphia, PA, USA) under an IACUC approved animal 
protocol. Genetically-engineered 129X1/SvJ mice carrying the 
TH-MYCN transgene in one concatamer (TH-MYCN+/- mice) 
or two concatamers (TH-MYCN+/+ mice) develop tumours 
closely resembling human neuroblastoma (2). TH-MYCN+/- 
mice were bred and offspring genotyped as described 
previously (17). TH-MYCN mice were euthanised at the time 
of tumour progression according to humane approved guide-
lines using 3-5% isoflurane inhalation followed by cervical 
dislocation. The mice were then disinfected with 70% ethanol 
prior to resecting the tumour free. Tumours were fragmented 
and filtered through a 40 µm nylon mesh filter into a conical 
tube, spun-pelleted, and resuspended in sterile Tris Ammonia 
Chloride buffer, buffered to pH 7.65. Tumour cell pellets were 
incubated at 37˚C for 5 min, rinsed and spun-pelleted multiple 
times in phosphate-buffered saline (PBS) and then plated in 
RPMI tissue culture media supplemented with 10% fetal calf 
serum (FCS), 1% L-glutamine and 1% penicillin/strepta-
mycin/gentamycin. The cells were propagated under routine 
tissue culture conditions and ~50% resulted in an established 
cell line over ~8 weeks. The TH-MYCN cell lines established 
were validated as tyrosine hydroxylase-positive by RT-PCR 
(>95% positive) and had surface expression of the GD2 disi-
aloganglioside, as detected by flow cytometry. The control 
murine cell lines used were Trp53 wild-type (wt) MEFPARP-/- 
obtained from Dr Gilbert de Murcia (18) and NIH3T3 cells. 
The control human neuroblastoma cell lines used were 
TP53 mutant, MYCN-amplified SK-N-BE(2)-C, and TP53 
wt non-MYCN-amplified SHSY5Y [obtained from Professor 
Penny Lovat (Newcastle University, Newcastle upon Tyne, 
UK) and Dr June Biedler (Memorial Sloan Kettering Cancer 
Center, New York, NY, USA) and authenticated by multiplex 
short tandem repeat profiling by NewGene Ltd. (Newcastle 
upon Tyne, UK) using the GenePrint® 10 system] and TP53 
wt MYCN-amplified NGP cells (19). The NHO2A cells were 
cultured as previously described (5). The 844MYCN+/+, 282MYCN+/-, 
SHSY5Y, SK-N-BE(2)-C and NGP cells were cultured in 
RPMI-1640 (Sigma-Aldrich, Irvine, UK) supplemented with 
10% fetal calf serum (FCS) (Gibco, Paisley, Scotland) and the 
3261MYCN+/+, 3394MYCN+/+ and 3399MYCN+/+ cells were cultured 
in RPMI-1640 supplemented with 20% FCS. MEFPARP-/- and 
NIH3T3 cells were cultured in Dulbecco's modified Eagle's 
medium (Sigma-Aldrich) supplemented with 10% FCS.
Trp53 sequencing. DNA was extracted from tumours and 
cell lines using a DNeasy Blood and Tissue kit (Qiagen, 
Manchester, UK) according to the manufacturer's instructions. 
DNA from NHO2A, 844MYCN+/+ and 282MYCN+/- cells was ampli-
fied for Trp53 exons 2-10 and sequenced in both directions 
by DBS genomics (Durham University, Durham, UK). The 
primer sequences are available upon request. The 3261MYCN+/+, 
3394MYCN+/+ and 3399MYCN+/+ DNA samples were amplified and 
sequenced in both directions for Trp53 exons 5-10 by LGC 
Genomics GmbH (Berlin, Germany).
MDM2 inhibitors, IR, western blot analysis and flow cytom-
etry. In brief, RG7388 was provided by Hoffman-La Roche 
(Nutley, NJ, USA), Nutlin-3 was purchased from Cambridge 
Bioscience Ltd. (Cambridge, UK) and MI-63 and NDD0005 
were synthesised as previously described (20,21). The cells 
were irradiated using a RS320 irradiator (Gulmay Medical, 
Surrey, UK). For protein analysis, whole cell lysates were 
harvested and proteins separated using 4-20% Mini-Protean 
TGX Precast Gels (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) and transferred onto Hybond-C Extra 
membrane  prior to incubation with antibodies and detection 
using enhanced chemiluminescence (both from GE Healthcare 
Life Sciences, Little Chalfont, UK) and X-ray film (Fujifilm, 
Bedford, UK). The primary antibodies used were p53 (1:1,000; 
CM5; Leica Microsystems Ltd., Buckinghamshire, UK), 
MYCN (1:100; NCMII00; Merck Millipore, Billerica, MA, 
USA), p21WAF1 (1:1,000; SX118; BD Biosciences, San Jose, CA, 
USA), Mdm2 1:500 (2A10), p19ARF 1:500 (ab80) (both from 
Abcam, Cambridge, MA, USA) and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) 1:500 (FL335; Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA). Cell growth inhibi-
tion was determined using the XTT cell proliferation assay 
(Roche, Burgess Hill, UK). The cells were seeded in 96-well 
plates (Corning, VWR International Ltd., Lutterworth, UK), 
allowed to adhere overnight prior to treatment with MDM2-
p53 antagonists for 48 h. For flow cytometry analysis, cells 
were fixed in ice-cold 70% (v/v) ethanol, and stained with 
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50 µg/ml propidium iodide and 50 µg/ml RNAse A (both from 
Sigma-Aldrich) at 37˚C for 30 min prior to analysis on the 
FACSCalibur (Becton-Dickinson, Oxford, UK). Data were 
analysed using Cyflogic (CyFlo Ltd., Turku, Finland).
Statistical analyses. Two-sided unpaired t-tests were 
performed using GraphPad Prism v6.0 software with a value 
of P<0.05 considered as the level of significance.
Results
Trp53 status of TH-MYCN cell lines. All TH-MYCN transgenic 
cell lines used in the present study were cultured as adherent 
monolayers (Fig. 1A). Trp53 Sanger sequencing identified that 
3/6 cell lines, the NHO2A, 844MYCN+/+ and 282MYCN+/- cells, 
had missense coding region point mutations (Fig. 1B-D). The 
NHO2A cells were homozygous for a p.F106S (phenylala-
nine to serine; c.317 C>T) Trp53 mutation corresponding to 
the human p.F109S TP53 missense mutation (Fig. 1B). The 
844MYCN+/+ cells were Trp53 homozygous mutant for a p.C173W 
(cysteine to tryptophan; c.519 C>G) mutation corresponding 
to the human p.C176W missense mutation (Fig. 1C). Of note, 
the 282MYCN+/- cells were heterozygously mutated for the same 
Trp53 p.C173W mutant allele as the 844MYCN+/+ cells (Fig. 1D). 
Both p.F106S and p.C173W mutations are within the DNA 
binding domain and were predicted to affect p53-mediated 
transactivation using the TP53Mutload database. The homo-
zygous mutations detected in NHO2A and 844MYCN+/+ cells are 
most likely to be due to allelic loss of one allele with mutation 
in the remaining allele.
To determine whether the mutations present in cell lines 
were also present in the original tumours or selected for during 
establishment of the cell line, tumour DNA was sequenced for 
Trp53 exons 2-10. Only 1/6 cell lines (NHO2A) had tumour 
DNA available and was found to be wt (Fig. 1E).
MYCN and the p53 pathway in TH-MYCN cell lines. Basal 
expression of MYCN and p53 pathway components, namely 
p53, Mdm2, p21WAF1 and p19ARF were assessed in TH-MYCN 
cell lines by western blot analysis (Fig. 1F). The Trp53 wt 
murine MEFPARP-/- and NIH3T3, and human MYCN amplified 
TP53 mutant SK-N-BE(2)-C cells were included as controls. 
Overexpression of the MYCN transgene was observed in 
all TH-MYCN cell lines, with levels comparable to those 
of the MYCN-amplified SK-N-BE(2)-C cells. NHO2A and 
844MYCN+/+ cells had the highest MYCN levels compared to the 
other TH-MYCN cell lines. Accumulation of p53 was observed 
in NHO2A, 844MYCN+/+ and 282MYCN+/- cells, consistent with 
their mutant Trp53 status. All mouse cell lines had very low 
or undetectable baseline Mdm2 expression (Fig. 1F). p21WAF1 
was expressed only in Trp53 wt 3399MYCN+/+ cell line (Fig. 1F). 
p19ARF was expressed in NHO2A, 844MYCN+/+, 3394MYCN+/+ and 
3399MYCN+/+ cells (Fig. 1F).
The response of the p53 pathway to Nutlin-3 and IR. Using 
Nutlin-3 and IR as different methods to induce p53 activa-
tion, activation of the p53 signalling pathway was assessed 
by western blot analysis in the TH-MYCN cell lines and 
control Trp53 wt MEFPARP-/- cells (Figs. 2 and 3). Consistent 
with their Trp53 wt status, MEFPARP-/- cells exhibited an intact 
p53 signalling pathway in response to both Nutlin-3 and IR, 
evident by p53 stabilisation and Mdm2 and p21WAF1 upregula-
tion (Figs. 2A and 3A). Of note, the p53 pathway response of 
MEFPARP-/- cells to IR was slightly diminished and delayed in 
comparison to Nutlin-3 (Figs. 2A and 3A), and is most likely 
a consequence of PARP-1 knockout in this cell line (22). 
As expected, homozygously Trp53 mutant NHO2A and 
844MYCN+/+ cells failed to show p53 induction in response to 
Nutlin-3 (Fig. 2B and C) or IR (Fig. 3B and C). Consistent with 
this observation, no p21WAF1 induction was observed in either 
cell line, and no Mdm2 induction was observed in 844MYCN+/+ 
cells. Of note, despite a lack of p53 induction, weak induc-
tion of Mdm2 was observed in NHO2A cells following both 
treatment with Nutlin-3 and exposure to IR (Figs. 2B and 3B). 
The heterozygously Trp53 mutant 282MYCN+/- cells also failed to 
show p53 stabilisation in response to Nutlin-3 or IR; however 
in spite of this, an increase in both Mdm2 and p21WAF1 expres-
sion was observed (Figs. 2D and 3D), most likely as a result 
of the presence of one remaining wt Trp53 allele. Finally, in 
line with their Trp53 wt status, the 3 remaining TH-MYCN 
cell lines, 3261MYCN+/+, 3394MYCN+/+ and 3399MYCN+/+, all 
showed evidence of IR- and Nutlin-3-induced p53 pathway 
activation, with stabilisation of p53, and induction of p21 and 
Mdm2 (Figs. 2E-G and 3E-G).
Nutlin-3-induced cell cycle distribution. To further charac-
terise the p53 functional response in the TH-MYCN cell lines 
to Nutlin-3, the sub-G1 and cell cycle distribution of all the 
6 TH-MYCN cell lines following 24 h treatment with 20 µM 
Nutlin-3 were analysed by propidium iodide-based flow 
cytometry. Sub-G1 events was used as a surrogate marker 
of apoptosis and the G1:S ratio calculated as an indicator of 
G1 cell cycle arrest. Trp53 wt NIH3T3 and MEFPARP-/- cells 
were included as positive controls. The functional assess-
ment of Nutlin-3-mediated cell cycle arrest and apoptosis 
of human neuroblastoma cell lines have previously been 
reported (23,24). In response to Nutlin-3 treatment, NIH3T3 
cells underwent G1 arrest, evident by a 4.6-fold increase 
in their G1/S ratio [16.58±4.43 (Nutlin-3) vs. 3.61±0.17 
(DMSO)] (Table I and Fig. 4A). Consistent with the observed 
activation of the p53 pathway in Fig. 2A, the MEFPARP-/- cells 
demonstrated a 3.2-fold increase in their G1:S ratio [7.19±3.32 
(Nutlin-3) vs. 2.23±0.23 (DMSO)], and a significant increase in 
the percentage of cells in G2/M phase [53.32%±4.19 (Nutlin-3) 
vs. 34.75%±1.63 (DMSO); P<0.005, paired t-test] (Table I 
and Fig. 4A), indicative of a Nutlin-3-induced G1 and particu-
larly G2 arrest in this cell line. In contrast to control Trp53 
wt murine cell lines, and as expected, no noticeable changes 
in the G1/S ratio or percentage of cells in G2/M phase were 
observed in any Trp53 mutant TH-MYCN NHO2A, 844MYCN+/+ 
or 282MYCN+/- cells (Table I and Fig. 4A). Of note, compared to 
the other murine cell lines, NHO2A and 282MYCN+/- cells had 
a high proportion of sub-G1 basal events (Table I and Fig. 4A), 
a surrogate marker of apoptosis, which following Nutlin-3 
treatment, increased slightly and remained unaltered, respec-
tively. Consistent with their Trp53 wt status and observed p53 
pathway activation, as shown in Fig. 2E-G, the 3 Trp53 wt 
TH-MYCN cell lines, 3261MYCN+/+, 3394MYCN+/+ and 3399MYCN+/+, 
all underwent a G1 phase arrest, as evident by a 5.2-, 5- and 
3.4-fold increase in G1/S ratio compared to control cells, 
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respectively (Table I and Fig. 4A). In addition, the 3399MYCN+/+ 
cells also exhibited an increased sub-G1 population (Table I 
and Fig. 4A).
Species-dependent MDM2 inhibitor selectivity. MDM2 inhib-
itors are currently under preclinical and clinical evaluation 
as a novel therapeutic for neuroblastoma. To further evaluate 
Figure 1. (A) Photomicrographs showing the morphological appearance of NHO2A, 282MYCN+/-, 844MYCN+/+, 3261MYCN+/+, 3394MYCN+/+ and 3399MYCN+/+ TH-MYCN 
murine neuroblastoma cell lines. Chromatograms showing Trp53 gene mutations identified in (B) NHO2A (homozygous mutation, codon 106, phenylala-
nine to serine), (C) 844MYCN+/+ (homozygous mutation, codon 173, cysteine to tryptophan) and (D) 282MYCN+/- (heterozygous mutation, codon 173, cysteine to 
tryptophan). All mutations are within the DNA binding domain of p53. The asterisk (*) marks the nucleotide change. (E) Chromatograms showing the Trp53 
wild-type (wt) status of the original tumour from which the NHO2A cell line was derived compared to the homozygous p.F106S (c.317C>T) mutation identified 
in the NHO2A cell line. (F) Western blot analysis of the basal expression of MYCN, Mdm2, p53, p21WAF1 and p19ARF (murine homologue of p14ARF) in the 
murine cell line panel in comparison to the TP53 mutant MYCN amplified SK-N-BE(2)-C human neuroblastoma cell line. *p53 and p19ARF antibodies are only 
reactive against murine p53 and p19ARF.
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the p53 pathway status of cell lines studied and establish their 
response to MDM2 inhibitors, sensitivity to Nutlin-3 and addi-
tional structurally unrelated MDM2 inhibitors, NDD0005, 
MI-63 and RG7388, and their effects on growth inhibition 
were assessed (Table II). Human TP53 wt non-MYCN ampli-
fied SHSY5Y and MYCN amplified NGP cells, which have 
previously been shown to be sensitive to the tested MDM2 
inhibitors (20,21,23), were included as positive controls. The 
concentrations of Nutlin-3, MI63, NDD0005 and RG7388, 
which led to a 50% growth inhibition (GI50) after 48 h of treat-
ment, are shown in Table II. In comparison to TP53 wt human 
neuroblastoma cells, the Trp53 wt control and TH-MYCN 
murine cell lines were less sensitive to Nutlin-3-mediated 
growth inhibition, as evidenced by higher GI50 concentrations 
Figure 2. The response of the p53 pathway of the MEFPARP-/- and TH-MYCN transgenic murine cell lines to the MDM2 inhibitor, Nutlin-3. Western blot analysis 
showing levels of p53 and p53 target genes, Mdm2 and p21WAF1 in (A) MEFPARP-/-, (B) NHO2A, (C) 844MYCN+/+, (D) 282MYCN+/-, (E) 3261MYCN+/+, (F) 3394MYCN+/+ 
and (G) 3399MYCN+/+ cells after 6, 24 and 48 h of treatment with 20 µM Nutlin-3. Control cells were treated with either media alone (M) or media containing 
an equal volume of DMSO (DMSO).
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(1.2-7.4-fold less sensitive) (Table II and Fig. 4B). As expected, 
Trp53 mutant TH-MYCN cell lines NHO2A, 844MYCN+/+ and 
282MYCN+/- had the highest GI50 values (14.1-21.8-fold less sensi-
tive) (Table II).
Further evaluation and comparison of Trp53 wt TH-MYCN 
and MEFPARP-/- cells to NDD0005, MI-63 and RG7388, 
demonstrated that although the MEFPARP-/- cells were signifi-
cantly (2.5-3.6-fold) less sensitive to NDD0005, there was no 
difference in the sensitivity of Trp53 wt TH-MYCN cell lines 
to NDD0005 compared with human SHSY5Y and NGP neuro-
blastoma cells (Table II and Fig. 4C). Of the tested MDM2 
inhibitors, MI-63 and RG7388 were the most potent against 
human neuroblastoma cell lines, consistent with the findings 
of our previous studies (20,23). The data also revealed that 
compared with SHSY5Y and NGP cells, Trp53 wt MEFPARP-/- 
cells were significantly (11.3-15.4- and 11.9-15.0-fold) less 
Figure 3. The p53 pathway response of MEFPARP-/- and TH-MYCN transgenic murine cell lines to ionising radiation (IR)-induced DNA damage. Western blot 
analysis showing the levels of p53 and p53 target genes, Mdm2 in (A) MEFPARP-/-, (B) NHO2A, (C) 844MYCN+/+, (D) 282MYCN+/-, (E) 3261MYCN+/+, (F) 3394MYCN+/+ 
and (G) 3399MYCN+/+ cells at 6, 24 and 48 h following exposure to 10 Gy IR. Control cells received no IR (M).
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sensitive to both MI-63 and RG7388, respectively (Table II 
and Fig. 4D and E). Furthermore, the data also indicated that 
Trp53 wt TH-MYCN cell lines were significantly (3.5-5.1-fold) 
less sensitive to MI-63 (Table II and Fig. 4D), and even less 
so (13.6-59.1-fold) to RG7388 (Table II and Fig. 4E). This 
highlights an inverse association between potency in TP53 wt 
human neuroblastoma cells and potency in Trp53 wt murine 
cells.
Discussion
Cell lines established from primary tumours resected from 
TH-MYCN mice have been used to develop valuable preclinical 
immunocompetent, syngeneic models of neuroblastoma (7,8), 
for which knowledge of their p53 pathway status is important. 
In this study, we demonstrated that 2/6 TH-MYCN cell lines 
were Trp53 homozygous mutant (NHO2A and 844MYCN+/+) 
and 1/6 was heterozygous mutant (282MYCN+/-). In the only case 
where DNA from the original tumour was available (NHO2A), 
the original tumour was Trp53 wt. This is consistent with our 
previous analysis of 13 primary TH-MYCN tumours, which did 
not show any Trp53 mutations (exons 4-8) (25). It is possible 
that Trp53 mutant subpopulations existed within the primary 
tumour, but were below the level of detection of Sanger 
sequencing, or that the mutation spontaneously developed and 
was selected for during ex vivo culturing pressures and cell 
line establishment. A MYCN oncogenic drive may be a strong 
contributing factor for the positive selection of Trp53 mutations 
Figure 4. Cell cycle distribution and sensitivity of murine cell lines in response to Nutlin-3. (A) Graph showing the cell cycle distribution of Trp53 wild-type 
(wt) murine control cells NIH3T3 and MEFPARP-/-, and the 6 TH-MYCN cell lines after 24 h of treatment with 20 µM Nutlin-3. Control cells were treated 
with media containing an equal volume of DMSO (DMSO). Error bars represent the SEM for n=3 repeat experiments. wt, Trp53 wt; mut, Trp53 mutant. 
Dose-response growth inhibition curves for p53 wt human SHSY5Y and NGP, murine MEFPARP-/- and TH-MYCN 3261MYCN+/+, 3394MYCN+/+ and 3399MYCN+/+ cells 
in response to 48 h treatment with (B) Nutlin-3, (C) NDD0005, (D) MI-63 and (E) RG7388.
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and may account for why 3/6 TH-MYCN cell lines tested in 
the present study were either homozygous or heterozygous 
Trp53 mutant. Certainly, MYCN is known to play a dual role in 
driving both proliferation and apoptosis, and there are several 
lines of evidence, including studies using TH-MYCN models, 
which suggest that MYCN driven p53-dependent apoptosis is 
an important mechanism for tumour suppression in neuro-
blastoma and that MYCN amplified neuroblastoma cells may 
circumvent MYCN driven p53-dependent apoptosis by selecting 
for cells with aberrations in the p53/MDM2/p14ARF pathway, as 
has been observed for MYCC-driven lymphoma (3,19,26-29). 
Specifically, as previously demonstrated, tumours formed 
with greater penetrance and reduced latency in TH-MYCN 
mice heterozygous for an inactivated germline p53 allele (27). 
The analysis of human neuroblastoma cell lines reported 
to date with aberrations in the p53/MDM2/p14ARF pathway 
demonstrates that 31/40 (78%) are MYCN-amplified (19). More 
recently, a study of the role of p53 function in neuroblastoma 
pathogenesis using TH-MYCN murine models observed that 
loss of p53 function led to reduced survival (30).
Nutlin-3 is a potent selective inhibitor of the MDM2-
p53 interaction (31), previously shown to be highly effective 
against TP53 wt neuroblastoma cell lines, inducing cell cycle 
arrest and/or apoptosis, and used to functionally screen 
large neuroblastoma cell line panels for p53 pathway aberra-
tions (23,24,32). In this study, we found that in all cell lines 
tested, the presence of a mutation was consistent with high 
basal levels of p53 and aberrant p53 signalling in response to 
Nutlin-3 and IR, and failure to growth arrest in response to 
Nutlin-3. Consistent with the mechanisms of action of MDM2 
inhibitors and existing data from human neuroblastoma cell 
lines, overall, Nutlin-3 was found to induce cell cycle arrest 
and/or apoptosis of Trp53 wt control and TH-MYCN murine 
cell lines (23,24). Of note, in the current study, in response to 
Nutlin-3 and IR, although there was no induction of p53, an 
increase in both Mdm2 and p21WAF1 expression was observed 
in heterozygously mutant 282MYCN+/- cells, suggesting there is 
some residual p53 function from the remaining wt allele (33); 
however this did not lead to growth arrest or apoptosis in 
response to Nutlin-3.
MDM2 inhibitors are currently under preclinical and 
clinical development as a novel therapeutic, both alone and 
in combination, for human malignancies including neuroblas-
toma. Of particular interest in view of the latter, data from 
the present study demonstrated that in comparison to human 
TP53 wt neuroblastoma cells, murine control (MEFPARP-/-) 
and TH-MYCN cell lines were significantly less sensitive 
to MI-63 and RG7388 induced growth inhibition. Although 
human and murine MDM2 show a high degree of amino acid 
sequence homology, with only 2 non-identical amino acids 
within the p53 binding domain (34), these subtle differences 
could account for a weaker binding affinity to murine Mdm2 
which is believed to contribute to the increased resistance 
and higher GI50 concentrations of murine cells to some 
MDM2 inhibitors that have been designed with high potency 
against human MDM2 (35). In support of this, the present 
Table I. Flow cytometric analysis of the proportion of cells in Sub-G1, G1, S, and G2/M phase, and the G1/S ratios in the panel 
cell lines used in this study.
 % Cell population in each phase
 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cell line and Treatment
Trp53 status condition Sub-G1 G1 S G2/M G1/S ratio
MEFPARP-/- DMSO 0.66±0.37 44.46±2.57 20.13±0.89 34.75± 1.63 2.23±0.23
(wt) Nutlin-3 0.86±0.31 37.29±7.29 8.52±4.03 53.32±4.19 7.19± 3.32
NIH3T3 DMSO 0.58±0.28 65.84±0.7 18.31±0.70 15.27±0.26 3.61±0.17
(wt) Nutlin-3 0.39±0.17 74.89±3.73 5.37±1.64 19.34±2.68 16.58±4.43
NHO2A DMSO 12.29± 3.2 53.35±1.98 23.28±0.79 11.07±1.33 2.29±0.01
(mutant) Nutlin-3 17.76± 1.68 52.06±0.23 21.14±1.44 9.04±0.94 2.48±0.15
282MYCN+/- DMSO 18.60±7.73 49.16±6.4 20.95±1.81 11.28±2.12 2.4±0.41
(mutant) Nutlin-3 17.37±9.66 51.58±5.73 19.69±2.29 11.37±3.22 2.68±0.41
844MYCN+/+ DMSO 1.91±0.23 67.80±2.88 17.09±1.16 13.18±1.59 4.03±0.45
(mutant) Nutlin-3 2.44±0.58 69.50±2.4 13.96±1.20 14.10±0.92 5.09±0.64
3261MYCN+/+ DMSO 0.86± 0.09 69.45±0.65 18.28±0.32 11.40±0.87 3.8±0.03
(wt) Nutlin-3 1.58± 0.05 88.61±0.28 4.57±0.41 5.24±0.41 19.67±1.68
3394MYCN+/+ DMSO 0.91±0.16 59.88±1.98 22.28±2.12 16.94± 1.31 2.79±0.38
(wt) Nutlin-3 1.86±0.36 82.01±1.72 6.82±1.68 9.31± 1.39 14.03±2.82
3399MYCN+/+ DMSO 1.80±0.37 73.46±4.43 14.98±2.88 9.77±1.39 5.55±1.69
(wt) Nutlin-3 4.63±0.97 83.93±3.61 5.76±1.79 5.69±1.26 18.67±7.01
Cell cycle analysis was performed using Trp53 wild-type (wt) and mutant murine cell lines after 24 h of treatment with 20 µM Nutlin-3 or an 
equal volume of DMSO. Values represent the mean of n=3 ± SEM.
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data showed that the more potent the MDM2 inhibitor was 
against human neuroblastoma cells, the less sensitive the 
murine cells were, and the greater the fold difference between 
GI50 values of Trp53 wt murine cells vs. TP53 wt human 
cells. These observations are consistent with the inter-species 
selectivity of spiro-oxindole-based MDM2 inhibitors (36) and 
dihydroisoquinolinone NVP-CGM097 (37), but not pyrazolo-
pyrrolidinone NVP-HDM201 (38,39), and should be taken into 
account when designing studies of MDM2 inhibitors either 
alone or in combination using either preclinical transgenic or 
human tumour xenograft models as p53-dependent normal 
tissue toxicity will not be adequately modelled.
Currently, murine neuroblastoma models include 
genetically engineered mouse models, syngeneic models, and 
subcutaneous, orthotopic, pseudometastatic and patient-derived 
xenografts (3,40-43). All models have associated advantages 
and disadvantages, and it is likely that the most comprehensive 
preclinical assessment of efficacy will include a combination 
of existing models. Several of the models predominantly use 
immunocompromised mice and thus are unsuitable for assess-
ment of immunotherapies, which are emerging as effective 
targeted therapies in patients with neuroblastoma. To overcome 
this, cell lines established from the TH-MYCN transgenic 
model/or other murine neuroblastoma cell lines can be used to 
generate orthotopic or pseudometastatic syngeneic models of 
neuroblastoma in an immunocompetent background (7,8). For 
this, the genetic and functional characterisation of murine cell 
lines, including Trp53 status and pathway function, are very 
important and highly warranted, as existing data are limited.
In conclusion, the Trp53 wt and mutant TH-MYCN cell 
lines characterised in this study can be used in syngeneic 
models of neuroblastoma, the former to test p53-dependent 
therapies in combination with immunotherapies, such as anti-
GD2 antibody, and the latter as models of immunocompetent, 
chemoresistant relapsed neuroblastoma in which aberrations 
in the p53 pathway are more common (14-16).
Table II. Summary of 48-h GI50 values for MDM2 antagonists in human and murine cells.
 Antagonist (µM)
 --------------------------------------------------------------------------------------------------------------------------------
Cell line 48 h Nutlin-3 NDD0005 MI-63 RG7388
SHSY5Y GI50 1.95±0.56 1.93±0.69 0.78±0.16 0.11±0.05
NGP GI50 2.51±0.3 2.78±0.02 1.06±0.12 0.14±0.03
MEFPARP-/- GI50 7.10±0.38 6.98±0.06 12.05±0.63 1.61±0.11
 Rel Fold/P-value vs. SHSY5Y 3.6/b 3.6/b 15.4/d 15.0/d
 Rel Fold/P-value vs. NGP 2.8/b 2.5/c 11.3/c 11.9/c
NIH3T3 GI50 14.1±2.2 ND ND ND
 Rel Fold/P-value vs. SHSY5Y 7.4/b
 Rel Fold/P-value vs. NGP 5.6/b
NHO2A GI50 41.4±2.7 ND ND ND
 Rel Fold/P-value vs. SHSY5Y 21.8/d
 Rel Fold/P-value vs. NGP 16.5/d
282MYCN+/- GI50 35.3±1.8 ND ND ND
 Rel Fold/P-value vs. SHSY5Y 18.6/d
 Rel Fold/P-value vs. NGP 14.1/d
844MYCN+/+ GI50 36.5±1.4 ND ND ND
 Rel Fold/P-value vs. SHSY5Y 19.2/d
 Rel Fold/P-value vs. NGP 14.5/d
3261MYCN+/+ GI50 3.53±0.54 2.38±0.39 3.71±0.3 6.36±1.65
 Rel Fold/P-value vs. SHSY5Y 1.8/ns 1.2/ns 4.7/c 59.1/b
 Rel Fold/P-value vs. NGP 1.4/ns 0.9/ns 3.5/b 47.0/a
3394MYCN+/+ GI50 3.09±0.19 1.57±0.63 4.0±0.41 1.84±0.50
 Rel Fold/P-value vs. SHSY5Y 1.6/ns 0.8/ns 5.1/c 17.1/b
 Rel Fold/P-value vs. NGP 1.2/ns 0.6/ns 3.8/b 13.6/a
3399MYCN+/+ GI50 4.3±1.2 1.58±0.65 3.94±0.58 3.49±0.37
 Rel Fold/P-value vs. SHSY5Y 2.2/ns 0.8/ns 5/b 32.4/c
 Rel Fold/P-value vs. NGP 1.7/ns 0.6/ns 3.7/b 25.8/b
Values represent the means ± SEM. P-values were determined using unpaired t-tests vs. human neuroblastoma SHSY5Y or NGP cells, aP≤0.05; 
bP≤0.01; cP≤0.001; dP≤0.0001; ns, not statistically significant. Rel Fold, fold change relative to the GI50 value of SHSY5Y cells and the GI50 
value of NGP cells; vs., versus; ND, not determined.
CHEN et al:  THE p53 PATHWAY IN TH-MYCN CELL LINES976
Acknowledgements
This study was supported by The Dubois Child Cancer Fund, 
SPARKS, the North of England Children's Cancer Research 
Fund (NECCRF), Neuroblastoma UK and Niamh's Next Step. 
We would like to thank Professor Michelle Haber for the NHO2A 
cell line and tumour DNA, Dr Gilbert de Murcia for providing 
the MEFPARP-/- cells, Dr Fabio Del Bello and Dr Alessandro 
Piergentili for providing MI-63, Dr Steven Middleton 
(Hoffmann-La Roche, Nutley, NJ, USA) for providing RG7388, 
and Dr Anna Watson, Dr Karen Haggerty and Dr Ian Hardcastle 
(Newcastle University) for synthesising NDD0005. We disclose 
that Dr L. Chen and Professor D.A. Tweddle are part of an inter-
national collaborative research consortium with Hoffmann-La 
Roche Ltd. Professor J. Lunec is a collaborative co-investigator 
of the CRUK funded Drug Discovery Programme at Newcastle 
University which developed NDD0005. Newcastle University, 
Cancer Research Technology and Astex Pharmaceuticals Inc. 
are part of an alliance agreement since 2012.
Competing interests
The authors declare that they have no competing interests.
References
 1. Cohn SL and Tweddle DA: MYCN amplification remains 
prognostically strong 20 years after its ‘clinical debut’. Eur J 
Cancer 40: 2639-2642, 2004. 
 2. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and 
Bishop JM: Targeted expression of MYCN causes neuroblastoma 
in transgenic mice. EMBO J 16: 2985-2995, 1997. 
 3. Chesler L and Weiss WA: Genetically engineered murine models 
- contribution to our understanding of the genetics, molecular 
pathology and therapeutic targeting of neuroblastoma. Semin 
Cancer Biol 21: 245-255, 2011. 
 4. Rasmuson A, Segerström L, Nethander M, Finnman J, 
Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T 
and Kogner P: Tumor development, growth characteristics and 
spectrum of genetic aberrations in the TH-MYCN mouse model 
of neuroblastoma. PLoS One 7: e51297, 2012. 
 5. Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, 
Lastowska M, Jackson MS, Hackett CS, Weiss WA, et al: Cell lines 
from MYCN transgenic murine tumours reflect the molecular 
and biological characteristics of human neuroblastoma. Eur J 
Cancer 43: 1467-1475, 2007. 
 6. Lehembre F and Regenass U: Metastatic disease: A drug 
discovery perspective. Semin Cancer Biol 22: 261-271, 2012. 
 7. Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, 
Back TC, Wei JS, Patidar R, Song Y, et al: High-throughput 
molecular and histopathologic profiling of tumor tissue in a novel 
transplantable model of murine neuroblastoma: New tools for 
pediatric drug discovery. Cancer Invest 30: 343-363, 2012. 
 8. Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, 
Boon L, den Brok MH, Hoogerbrugge PM and Adema GJ: A 
transplantable TH-MYCN transgenic tumor model in C57Bl/6 
mice for preclinical immunological studies in neuroblastoma. Int 
J Cancer 134: 1335-1345, 2014. 
 9. Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: 
Awakening guardian angels: drugging the p53 pathway. Nature 
reviews 9: 862-873, 2009. https://doi.org/10.1038/nrc2763.
10. Carr J, Bell E, Pearson ADJ, Kees UR, Beris H, Lunec J 
and Tweddle DA: Increased frequency of aberrations in the 
p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines 
established at relapse. Cancer Res 66: 2138-2145, 2006. 
11. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, 
Gomer CJ, Triche TJ and Reynolds CP: Loss of p53 function 
confers high-level multidrug resistance in neuroblastoma cell 
lines. Cancer Res 61: 6185-6193, 2001.
12. Levine AJ: p53, the cellular gatekeeper for growth and division. 
Cell 88: 323-331, 1997. 
13. Soussi T and Béroud C: Assessing TP53 status in human tumours 
to evaluate clinical outcome. Nat Rev Cancer 1: 233-240, 2001. 
14. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, 
Board JR, Evans L, Cole M, Cheung NK, Boos J, et al: High 
Frequency of p53/MDM2/p14ARF Pathway Abnormalities in 
Relapsed Neuroblastoma. Clin Cancer Res 16: 1108-1118, 2010. 
15. Tweddle DA, Malcolm AJ, Bown N, Pearson AD and Lunec J: 
Evidence for the development of p53 mutations after cytotoxic 
therapy in a neuroblastoma cell line. Cancer Res 61: 8-13, 2001.
16. Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, 
Rubnitz KR, Sanford EM, Ali SM, Miller VA, Mossé YP, 
Granger MP, et al: Enrichment of targetable mutations in the 
relapsed neuroblastoma genome. PLoS Genet 12: e1006501, 
2016. 
17. Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, 
Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, et al: 
Polyamine antagonist therapies inhibit neuroblastoma initiation 
and progression. Clin Cancer Res 22: 4391-4404, 2016. 
18. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, 
Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, et al: 
Requirement of poly(ADP-ribose) polymerase in recovery from 
DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 
7303-7307, 1997. 
19. Chen L and Tweddle DA: p53, SKP2, and DKK3 as MYCN 
target genes and their potential therapeutic significance. Front 
Oncol 2: 173, 2012. 
20. Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, 
Middleton SA, Nichols GL, Del Bello F, Piergentili A, 
Newell DR, et al: Structurally diverse MDM2-p53 antagonists 
act as modulators of MDR-1 function in neuroblastoma. Br J 
Cancer 111: 716-725, 2014. 
21. Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, 
Lunec J and Tweddle DA: Pre-clinical evaluation of the 
MDM2-p53 antagonist RG7388 alone and in combination with 
chemotherapy in neuroblastoma. Oncotarget 6: 10207-10221, 
2015. 
22. Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, 
Sarker M, de Murcia G and Oliver FJ: PARP-1 modifies the effec-
tiveness of p53-mediated DNA damage response. Oncogene 21: 
1108-1116, 2002. 
23. Gamble LD, Kees UR, Tweddle DA and Lunec J: MYCN 
sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 
and MI-63. Oncogene 31: 752-763, 2012. 
24. Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, 
Marine JC, Westermann F, De Paepe A, Vandesompele J and 
Speleman F: Functional analysis of the p53 pathway in neuro-
blastoma cells using the small-molecule MDM2 antagonist 
nutlin-3. Mol Cancer Ther 10: 983-993, 2011. 
25. Mazanek P, Dam V, Morgan BT, Liu X, Pawar N and Hogarty MD: 
Assessment of p19/ARF-MDM-p53 and RAS pathways for alter-
ations in neuroblastomas arising in the transgenic TH-MYCN 
mouse model. In: Advances in Neuroblastoma Research June 
16-19th 2004, Genoa, Italy, 2004.
26. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, 
Lunec J and Tweddle DA: p53 is a direct transcriptional target of 
MYCN in neuroblastoma. Cancer Res 70: 1377-1388, 2010. 
27. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, 
Tihan T, Nguyen K, Yakovenko S, Matthay K and Weiss WA: 
Chemotherapy-induced apoptosis in a transgenic model of 
neuroblastoma proceeds through p53 induction. Neoplasia 10: 
1268-1274, 2008.
28. Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A and 
Shohet JM: Mdm2 deficiency suppresses MYCN-Driven neuro-
blastoma tumorigenesis in vivo. Neoplasia 11: 753-762, 2009.
29. Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL: 
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in 
Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669, 1999. 
30. Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, 
Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, et al: p53 
loss in MYC-driven neuroblastoma leads to metabolic adap-
tations supporting radioresistance. Cancer Res 76: 3025-3035, 
2016. 
31. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, 
Kong N, Kammlott U, Lukacs C, Klein C, et al: In vivo activation 
of the p53 pathway by small-molecule antagonists of MDM2. 
Science 303: 844-848, 2004.
32. Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C, 
Pearson AD, Lunec J and Tweddle DA: p53 is nuclear and func-
tional in both undifferentiated and differentiated neuroblastoma. 
Cell Cycle 6: 2685-2696, 2007.
INTERNATIONAL JOURNAL OF ONCOLOGY  52:  967-977,  2018 977
33. Sun Y, Yi H, Yang Y, Yu Y, Ouyang Y, Yang F, Xiao Z and Chen Z: 
Functional characterization of p53 in nasopharyngeal carcinoma 
by stable shRNA expression. Int J Oncol 34: 1017-1027, 2009.
34. Vassilev LT: Small-molecule antagonists of p53-MDM2 binding: 
research tools and potential therapeutics. Cell Cycle 3: 419-421, 
2004.
35. Khoo KH, Verma CS and Lane DP: Drugging the p53 pathway: 
Understanding the route to clinical efficacy. Nat Rev Drug 
Discov 13: 217-236, 2014. 
36. Delaisi C, Meaux I, Dos-Santos O, Barrière C, Duffieux F, 
Hoffmann D, Rak A, Wolfrom M, Flèche , Zhou-Liu Q, et al: 
In vitro characterization of spiro-oxindole-based modulators 
of the MDM2-p53 interaction and their interspecies selectivity. 
103rd Annual Meeting of the American Association for Cancer 
Research, Mar 31-Apr 4, 2012. Cancer Res 72: Abstract nr 4648, 
Chicago, IL, 2012.
37. Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, 
Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, 
Pissot-Soldermann C, et al: Discovery of a dihydroisoquino-
linone derivative (NVP-CGM097): A highly potent and selective 
MDM2 inhibitor undergoing phase 1 clinical trials in p53wt 
tumors. J Med Chem 58: 6348-6358, 2015. 
38. Stachyra-Valat T, Baysang F, D'Alessandro A-C, Dirk E, Furet P, 
Guagnano V, Kallen J, Leder L, Mah R, Masuya K, et al: Abstract 
1239: NVP-HDM201: Biochemical and biophysical profile of a 
novel highly potent and selective PPI inhibitor of p53-Mdm2. 
Cancer Res 76 (Suppl 14): 1239-1239, 2016. 
39. Furet P, Masuya K, Kallen J, Stachyra-Valat T, Ruetz S, 
Guagnano V, Holzer P, Mah R, Stutz S, Vaupel A, et al: Discovery 
of a novel class of highly potent inhibitors of the p53-MDM2 
interaction by structure-based design starting from a conforma-
tional argument. Bioorg Med Chem Lett 26: 4837-4841, 2016. 
40. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, 
De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, et al: 
Targeted expression of mutated ALK induces neuroblastoma in 
transgenic mice. Sci Transl Med 4: 141ra91, 2012. 
41. Khanna C and Hunter K: Modeling metastasis in vivo. 
Carcinogenesis 26: 513-523, 2005. 
42. Khanna C, Jaboin JJ, Drakos E, Tsokos M and Thiele CJ: 
Biologically relevant orthotopic neuroblastoma xenograft 
models: Primary adrenal tumor growth and spontaneous distant 
metastasis. In Vivo 16: 77-85, 2002.
43. Beltinger C and Debatin KM: Murine models for experimental 
therapy of pediatric solid tumors with poor prognosis. Int J 
Cancer 92: 313-318, 2001. 
